HIND (Vyome Holdings, Inc.) PDUFA Date | FDA Catalyst & Approval Status

Jul 1, 2026

Vyome Granted Chinese Patent Strengthening Immuno-Inflammation Portfolio

Vyome has been granted a patent in China, which enhances its immuno-inflammation portfolio. This development is expected to strengthen the company's position in the market. Further details on the implications of this patent grant were not disclosed in the article.

May 28, 2026

Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

Vyome Holdings has reported its financial results for the first quarter of 2026, highlighting key FDA filings and a robust balance sheet. The report indicates the company's ongoing efforts to strengthen its position in the biopharma sector. Further details on the specific FDA filings and financial metrics were not disclosed in the article.

May 12, 2026

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome Pharmaceuticals has entered into a strategic partnership with Impetis Biosciences. This collaboration aims to explore opportunities in a market estimated to be worth approximately $57 billion. The deal is expected to enhance Vyome's position in the biopharma sector, although specific details about the partnership's terms have not been disclosed.

Apr 6, 2026

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome is set to present Phase 2 clinical data on VT-1953 for the treatment of MFW at the AACR 2026 conference. This presentation highlights the company's ongoing research efforts in this area. Details regarding the specific findings or implications of the data have not been disclosed.

Feb 24, 2026

▲ +8.3%on this news· ran to +20% by day 1

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

Livechain, a subsidiary of Vyome Holdings, has acquired Humanyze, an AI-enabled HR analytics company, through a debt purchase agreement. This all-stock transaction, valued at approximately $325,000, allows Livechain to take control of Humanyze's operations and assets. The acquisition aims to enhance Livechain's position in the AI HR sector and potentially lead to an uplisting on a national exchange.

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Holdings, Inc. announced positive preclinical results for VT-1908, a potential treatment for uveitis, published in the Journal of Ophthalmic Inflammation and Infection. The study demonstrated that VT-1908 effectively reduced uveitis scores without toxicity, positioning it as a viable alternative to traditional steroids. The company aims to advance VT-1908 into clinical development, targeting a significant market opportunity.

Feb 13, 2026

VT - 1953 in Treating Symptoms of Malignant Fungating Wounds (MFW) PHASE 2 IST STUDY RESULTS & NEXT STEPS Vyome Holdings, Inc. February 2026 VYOME HOLDINGS, INC. ("Vyome") 2 Any statements contained in this presentation

Vyome Holdings, Inc. has announced promising results from the Phase 2 study of VT - 1953 for treating malignant fungating wounds (MFW). The study demonstrated significant improvements in the primary endpoint of malodor and secondary endpoints related to quality of life and lesion pain. Specifically, patients treated with VT - 1953 reported marked enhancements in symptom relief compared to those receiving a vehicle treatment. The results provide a foundation for continued clinical exploration of VT - 1953 as a viable treatment option for MFW.

Feb 11, 2026

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Holdings has filed for Orphan Drug Status for its lead program VT-1953, which targets malignant fungating wounds (MFW) affecting advanced cancer patients. The company reported positive Phase 2 results and anticipates significant market potential, with a projected U.S. asset value of $455 million. Vyome aims to advance this program strategically over the next six months.

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Vyome Holdings has successfully secured funding for its VT-1953 Phase 3 study, ensuring capital for interim results expected in mid-2027. The company utilized its At-The-Market facility, achieving this with minimal dilution. Management emphasized their commitment to shareholder value and noted the drug's potential worth of $1 billion upon trial completion.

Jan 28, 2026

▼ -22.1%on this news· ran to -34% by day 1shared move

U.S. Market & Product Assessment and Valuation of VT - 1953 for the Treatment of Symptoms of Malignant Fungating Wounds H1 2026 2 PROJECT OVERVIEW Destum Partners performed a U.S. market and product assessment, commercia

Destum Partners has completed a U.S. market and product assessment for VT - 1953, a potential treatment for malignant fungating wounds (MFW). This condition is a severe complication of advanced solid tumors, often resulting in significant patient suffering and high unmet need. Currently, no FDA-approved therapies target MFW symptoms, creating an opportunity for VT - 1953 to fill this gap. The assessment projects that VT - 1953 will achieve a rNPV valuation of $455 million in the U.S. as of H1 2026, with expectations for growth to $1.086 billion by H1 2028 upon completing Phase 3 trials.

Jan 27, 2026

Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Holdings announced a valuation analysis for its lead candidate VT-1953, aimed at treating malignant fungating wounds. Conducted by Destum Partners, the assessment suggests a potential market value of USD 1 billion following successful Phase 3 trials. The analysis highlights a significant unmet need in oncology supportive care, with estimated peak sales of USD 600 million.

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Holdings' subsidiary, LiveChain, has signed a letter of intent to acquire a senior secured note from Humanyze, an AI-driven HR analytics company. The deal, valued at approximately $325,000 in stock, positions LiveChain as Humanyze's senior secured creditor. This acquisition aims to enhance LiveChain's financial independence and create value for shareholders, although the transaction is subject to final agreements.

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing (Quarter Ended

Vyome Holdings, Inc. reported strong financial results for the quarter ended September 30, 2025, following its successful Nasdaq listing. Highlights included positive interim data for the VT-1953 drug targeting malignant fungating wounds (MFW), a significant unmet medical need. The company emphasized its efficient transition to public markets with a clean capital structure, while facing substantial operating losses. CEO Venkat Nelabhotla expressed confidence in the potential of their immuno-inflammation platform to drive long-term value for shareholders and patients.

Sep 29, 2025

Vyome Holdings Acquires MIT AI Spinout Oculo Health Launches business unit to create AI psychiatrist focused on reducing inflammation Vyome remains fully funded through 2026 to unlock value from core assets

Vyome Holdings has acquired Oculo, an AI startup from MIT, and launched a new division focused on developing an AI psychiatrist aimed at reducing inflammation. This initiative targets behavioral drivers and biomarkers related to inflammation, anticipating a market growth potential exceeding $100 billion in digital therapeutics. The acquisition will not affect the progression of Vyome's core biotech assets, as the company remains fully funded through 2026. Their goal is to create a new therapeutic category combining mental health and digital health solutions.

VYOME THERAPEUTICS INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS AS OF (Amount in USD)

Vyome Therapeutics Inc. reported its condensed consolidated balance sheets and financial performance for the first half of 2025. The company showed an increase in total current assets, with cash and cash equivalents significantly improving. However, it also reported a net loss of $602,732, along with an increase in total liabilities and a rising accumulated deficit, highlighting financial strain. The firm continues its focus on drug development for immune-inflammatory diseases amidst these financial challenges.

Jul 7, 2025

Vyome A US-India healthcare platform with clinical-stage immuno-inflammation assets PENDING MERGER $RSLS TO $HIND CORPORATE PRESENTATION JULY 2025 VYOME THERAPEUTICS, INC. (“Vyome”) Any statements contained

Vyome Therapeutics is in the process of merging with ReShape Lifesciences, focusing on developing clinical-stage immuno-inflammation assets. The company targets significant market opportunities, including therapies for atopic dermatitis, ulcerative colitis, and systemic lupus erythematosus, which all show considerable market sizes. With a well-experienced management team, Vyome aims to leverage its assets to unlock value within the next two years. Key milestones include pivotal studies and possible FDA filings, indicating a strategic roadmap for future growth.

Jun 9, 2025

ReShape Lifesciences Announces Pricing of $2.6 Million Public Offering

ReShape Lifesciences has announced the pricing of its public offering, which includes the sale of 1,054,604 shares of common stock at $2.50 per share, aiming to raise approximately $2.6 million. The offering is set to close around June 9, 2025, pending customary closing conditions. This move is part of a broader strategy to finance its operations in obesity and metabolic health solutions. The company has filed all necessary documentation with the SEC to ensure compliance.

May 28, 2025

Vyome Therapeutics, Inc. and Subsidiary Vyome Therapeutics Inc. and Subsidiary Consolidated financial statements (unaudited) Three months ended

Vyome Therapeutics, Inc. reported its unaudited financial results for the three months ended March 31, 2025, revealing a significant increase in revenue but a concerning rise in net loss. Revenue for the quarter reached $198,582, up from $76,979 compared to the same period in 2024. However, total liabilities increased to $6,128,088, and the net loss widened to $293,972, reflecting growing financial challenges. The company continues to advance its clinical programs, despite the increases in operating costs and net losses.

May 9, 2025

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split Effective as of Commencement of Trading on

ReShape Lifesciences Inc. has announced a 1-for-25 reverse stock split effective May 9, 2025. This decision was approved by stockholders during a special meeting held on April 1, 2025. Following the split, existing shares will be consolidated to enhance the stock's attractiveness. The company continues to focus on providing solutions for obesity and metabolic health disorders.

Feb 15, 2025

ReShape Lifesciences Announces Pricing of Upsized $6.0 Million Public Offering

ReShape Lifesciences has announced the pricing of an upsized public offering of 2,575,107 units at $2.33 per unit, aimed at raising approximately $6.0 million. Each unit includes one common share and one warrant to purchase an additional common share, contingent on stockholder approval. The offering is expected to close on or around February 18, 2025, pending standard closing conditions. This financial move is part of ReShape's ongoing strategy to enhance its offerings in weight loss and metabolic health solutions.

Dec 11, 2024

Vyome A US-India healthcare platform with clinical-stage immuno-inflammation assets PENDING MERGER $RSLS TO $HIND CORPORATE PRESENTATION DECEMBER 2024 VYOME THERAPEUTICS, INC. (“Vyome”) Any statements conta

Vyome Therapeutics, a US-India healthcare platform specializing in immuno-inflammation assets, is preparing for a merger with $HIND, pending completion in December 2024. The company has multiple clinical-stage programs targeting large markets such as inflammatory bowel disease and atopic dermatitis, with potential market sizes in the billions. Vyome's leadership team consists of experienced professionals from the healthcare industry, aiming to unlock value through pivotal studies and regulatory approvals over the next two years. The company possesses a debt-free status, which enhances its financial appeal in the pending merger.

Nov 14, 2024

ReShape Lifesciences Reports Third Quarter Ended

ReShape Lifesciences reported its financial results for the third quarter of 2024, showcasing a 16.6% increase in revenue compared to Q2 2024, marking three consecutive quarters of growth. The company significantly reduced its operating expenses by 40.6% over the first nine months of the year and received approval for the next-generation Lap-Band 2.0 FLEX. Furthermore, a merger agreement with Vyome Therapeutics and an asset purchase with Biorad were announced, indicating strategic moves for future growth despite a noted decline in revenue due to competition from pharmaceutical alternatives.

Sep 23, 2024

ReShape Lifesciences Announces 1-for-58 Reverse Stock Split Effective as of Commencement of Trading on

ReShape Lifesciences Inc. has announced a 1-for-58 reverse stock split effective September 23, 2024. This decision was approved by stockholders at the annual meeting in February 2024. Each 58 shares of common stock will be converted into one share, with adjustments made for outstanding warrants, stock options, and convertible preferred stock. The new CUSIP number will be 76090R309, and shareholders will receive instructions for exchanging their stock certificates. This move is aimed at enhancing shareholder value and market perception.

Aug 14, 2024

ReShape Lifesciences Reports Second Quarter Ended

ReShape Lifesciences Inc. reported its financial results for the second quarter of 2024 and outlined significant operational changes. The company has entered into a merger agreement with Vyome Therapeutics and signed an asset purchase agreement with Biorad Medisys, which includes selling off major assets. Notably, operating expenses have been reduced by 45.4%, though revenues saw a contraction of 12.8% due to declining sales volume influenced by competitive GLP-1 products. A conference call to discuss these developments is scheduled for August 15, 2024.

Jul 9, 2024

ReShape Lifesciences Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno- Inf

ReShape Lifesciences and Vyome Therapeutics have announced a merger agreement in an all-stock transaction, allowing them to advance their focus on immuno-inflammatory assets. Following the merger, ReShape will be renamed Vyome Holdings, Inc., and traded under the ticker 'HIND.' Concurrently, ReShape will sell its assets to Biorad Medisys for $5.16 million. Both agreements have been unanimously approved by the respective boards, with benefits projected for shareholders stemming from the merger’s potential in the combined company’s pharma efforts.

May 20, 2024

ReShape Lifesciences Reports First Quarter Ended

ReShape Lifesciences reported its financial results for the first quarter ended March 31, 2024, highlighting a 51% reduction in operating expenses compared to the previous year. The company successfully launched its next-generation Lap-Band 2.0 FLEX, reflecting strong adoption in bariatric surgeries. However, it faced a 15% revenue contraction attributed to increased competition from GLP-1 medications. Furthermore, ReShape has strengthened its intellectual property portfolio through a newly issued patent, aiming for long-term growth despite current revenue challenges.

Apr 4, 2024

ReShape Lifesciences Reports Year Ended

ReShape Lifesciences reported its financial results for the year ended December 31, 2023, showing a revenue decline due to increased competition from GLP-1 medications for weight loss. Despite this, the company successfully completed its first surgeries using the new Lap-Band 2.0 FLEX, which is expected to enhance patient experiences. Management aims to reduce operating expenses significantly in 2024 and has received a patent allowance for an intragastric balloon system. The company continues to navigate financial challenges while focusing on strategic growth initiatives.

Nov 21, 2023

ReShape Lifesciences Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds

ReShape Lifesciences, Inc. has entered into a warrant exercise agreement that will generate approximately $1.2 million in gross proceeds. Existing warrants will be exercised for cash, giving the investor new unregistered warrants for additional shares at a predetermined price. The funds raised are intended for commercial growth and corporate purposes. The company needs to seek stockholder approval for a potential reduction in the exercise price of the new warrants.

Sep 29, 2023

ReShape Lifesciences Announces Pricing of $3.0 Million Public Offering

ReShape Lifesciences has announced a public offering, pricing 9,100,000 units at $0.33 each, expected to raise approximately $3.0 million before expenses. The offering involves shares of common stock and warrants, which will be immediately exercisable for five years. The successful completion of this offering will depend on customary closing conditions. This move may enhance ReShape's financial stability and support its initiatives in weight loss and metabolic health solutions.

Sep 21, 2023

ReShape Lifesciences Signs Exclusive License Agreement With Biorad Medisys for Obalon Gastric Balloon System Royalty-Bearing License Agreement Covers the Countries in the Indian Subcontinent, Representing Approximately 2

ReShape Lifesciences has entered into an exclusive license agreement with Biorad Medisys for the distribution of the Obalon Gastric Balloon System across various countries in the Indian subcontinent. This agreement involves an upfront payment of $200,000 and a royalty of 4% on gross sales. The partnership aims to leverage Biorad's experience to expand the reach of ReShape's innovative technology in a region that represents a significant portion of the global population. The deal signifies a strategic step towards the global re-launch and commercialization of the Obalon system.

Apr 20, 2023

ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market

ReShape Lifesciences Inc. has announced a $2.5 million registered direct offering alongside a concurrent private placement. The offering involves the sale of 800,695 shares of common stock and accompanying warrants, priced at $3.07 each. The gross proceeds from this offering are intended to support the company's initiatives in weight loss and metabolic health solutions. Closing is expected around April 24, 2023, subject to customary conditions. Maxim Group LLC is the sole placement agent for this transaction.

Feb 6, 2023

ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering

ReShape Lifesciences Inc. announced an upsized underwritten public offering of 1,275,000 units, priced at $8.00 per unit. This offering is expected to gross approximately $10.2 million, which will be used for growth strategies and working capital. The offering is set to close on February 8, 2023, subject to customary conditions. Additionally, the underwriters have the option to purchase additional shares to cover over-allotments.

Jan 27, 2023

HINDFDA Updates

BUSINESS Our Company ReShape Lifesciences Inc. is a worldwide premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. O

ReShape Lifesciences Inc. is a global leader in weight-loss solutions, providing a comprehensive range of products and services aimed at managing obesity and metabolic diseases. Their portfolio includes the FDA-approved Lap-Band system, a safer alternative for treating obesity, and the newly launched ReShapeCare virtual coaching program, which supports patients in managing weight through telehealth. Additionally, the company has developed innovative products such as the Obalon Balloon system and is working on a new device for diabetes management. Their focus on enhancing patient care through technology and proven solutions positions them well in the biopharmaceutical market.

Dec 23, 2022

ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on

ReShape Lifesciences Announces 1-for-50 Reverse Stock Split Effective as of Commencement of Trading on December 23, 2022 SAN CLEMENTE, CA - December 22, 2022- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company,

Nov 14, 2022

ReShape Lifesciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update Conference Call to be Held at 8:00 am ET Today

ReShape Lifesciences Reports Third Quarter 2022 Financial Results and Provides Corporate Update Conference Call to be Held at 8:00 am ET Today SAN CLEMENTE, Calif., November 14, 2022 -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metaboli

Nov 8, 2022

ReShape Lifesciences Announces $750,000 Registered Direct Offering

Lifesciences Announces $750,000 Registered Direct Offering CA- November 8, 2022 (GLOBE NEWSWIRE) - ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purch

Aug 15, 2022

ReShape Lifesciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update Second Quarter Revenues Increased 19% Sequentially, Indicating DTC Campaign Continues to Drive Demand for Lap-Band Procedur

ReShape Lifesciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update Second Quarter Revenues Increased 19% Sequentially, Indicating DTC Campaign Continues to Drive Demand for Lap-Band Procedures Conference Call to be Held at 4:30 pm ET Today SAN CLE

Jul 27, 2022

ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer

ReShape Lifesciences Announces Appointment of Paul F. Hickey as President and Chief Executive Officer CLEMENTE, Calif., July 27, 2022 -- ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that its

May 23, 2022

ReShape Lifesciences Reports First Quarter 2022 Financial Results and Provides Corporate Update March 2022 Revenues Exceeded January's and February's, Combined, Indicating DTC Campaign and Other Visibility Activities are

ReShape Lifesciences Reports First Quarter 2022 Financial Results and Provides Corporate Update March 2022 Revenues Exceeded January's and February's, Combined, Indicating DTC Campaign and Other Visibility Activities are Driving Significant Demand for Lap-Band Procedures Confer

Mar 28, 2022

ReShape Lifesciences Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update Conference Call to be Held at 5:30 pm ET Today

ReShape Lifesciences Reports Year Ended 2021 Financial and Operating Results and Provides Corporate Update Conference Call to be Held at 5:30 pm ET Today SAN CLEMENTE, Calif., March 28, 2022 -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and

Mar 22, 2022

ReShape Lifesciences to Announce Financial Results for the Year Ended

ReShape Lifesciences to Announce Financial Results for the Year Ended December 31, 2021 and Provide Corporate Update Full Year Revenue Increased by Approximately 20%, from $11.3 M to $13.6 M $22.8 M in Cash and Cash Equivalents as of December 31, 2021 Company Eliminated All De

Nov 11, 2021

ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results Webinar to follow at 8:45 a.m. ET today San Clemente, CA

ReShape Lifesciences Reports Third Quarter and Nine Month 2021 Financial and Operational Results Webinar to follow at 8:45 a.m. ET today San Clemente, CA November 11, 2021 - ReShape Lifesciences Inc. (NASDAQ: RSLS), the premier physician-led weight loss and metabolic health-sol

Aug 16, 2021

ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update Webinar to follow at 8:30 a.m. today San Clemente, CA

ReShape Reports Second Quarter 2021 Financial Results and Provides Business Update Webinar to follow at 8:30 a.m. today San Clemente, CA August 16, 2021 - ReShape Lifesciences Inc. (NASDAQ: RSLS), a leading developer and distributor of minimally invasive medical devices to trea

Jun 15, 2021

ReShape Lifesciences Inc. and Obalon Therapeutics, Inc. Announce Anticipated Closing of Merger SAN CLEMENTE, CA and

Lifesciences Inc. and Obalon Therapeutics, Inc. Anticipated Closing of Merger SAN CLEMENTE, CA and SAN DIEGO, CA - June 15, 2021 - ReShape Lifesciences Inc. (OTCQB: RSLS) and Obalon Therapeutics, Inc. (NASDAQ: OBLN) announced today the anticipated closing of their previously

May 20, 2021

Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences

Obalon Therapeutics Continues to Urge Stockholders to Vote FOR All Proposals Related to Merger with ReShape Lifesciences SAN DIEGO, CA - May 20, 2021 - Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology company with the first and only FDA-appr

May 18, 2021

Obalon Therapeutics Stockholders Special Meeting Adjourned to

Obalon Therapeutics Stockholders Special Meeting Adjourned to May 25, 2021 Urging all Shareholders to Vote For Proposals Related to Merger with ReShape LifeSciences Inc. Meeting to be held via Webcast at 8:30 a.m. Pacific SAN DIEGO, CA - May 18, 2021 - Obalon Therapeutics, I

May 12, 2021

HINDFDA Updates

Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, CA MAY 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA

Obalon Announces First Quarter 2021 Financial Results SAN DIEGO, CA MAY 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon syst

Mar 12, 2021

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results

Obalon Announces Fourth Quarter and Full Year 2020 Financial Results SAN DIEGO, CA March 12, 2021 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragas

Jan 19, 2021

VOTING AND SUPPORT AGREEMENT AMONG OBALON THERAPEUTICS, INC. AND CERTAIN STOCKHOLDERS OF RESHAPE LIFESCIENCES INC. DATED AS OF JANUARY , 2021 VOTING AND SUPPORT AGREEMENT dated as of January , 2021 (this " Agreement

VOTING AND SUPPORT AGREEMENT OBALON THERAPEUTICS, INC. CERTAIN STOCKHOLDERS OF RESHAPE LIFESCIENCES INC. VOTING AND SUPPORT AGREEMENT dated as of January __, 2021 (this "Agreement"), among Obalon Therapeutics, Inc., a Delaware corporation ("Obalon"), and each of the individual

May 8, 2020

To assist the Company in the transition, Mr.

William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director Obalon's Executive Chairman, Andy Rasdal, will reassume CEO position SAN DIEGO, CA, May 8, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertica

Aug 2, 2019

Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering SAN DIEGO, CA. (

Obalon Therapeutics Inc. Announces Pricing of $15,000,000 Public Offering SAN DIEGO, CA. (August 2, 2019) - Obalon Therapeutics Inc. (Nasdaq: OBLN) (the "Company"), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled in

Jul 25, 2019

Obalon Announces Reverse Stock Split Effective Today OBLN common stock expected to begin trading on a split-adjusted basis on

Obalon Announces Reverse Stock Split Effective Today OBLN common stock expected to begin trading on a split-adjusted basis on July 25, 2019 SAN DIEGO, CA, July 24, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN), a vertically integrated medical technology comp

Jan 3, 2019